Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Therapeutic strategies for COVID-19: progress and lessons learned
G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
Cancer therapy with antibodies
The greatest challenge in cancer therapy is to eradicate cancer cells with minimal damage
to normal cells. Targeted therapy has been developed to meet that challenge, showing a …
to normal cells. Targeted therapy has been developed to meet that challenge, showing a …
NANOBODIES®: A Review of Generation, Diagnostics and Therapeutics
B **, S Odongo, M Radwanska, S Magez - International journal of …, 2023 - mdpi.com
NANOBODY®(a registered trademark of Ablynx NV) molecules (Nbs), also referred to as
single domain-based VHHs, are antibody fragments derived from heavy-chain only IgG …
single domain-based VHHs, are antibody fragments derived from heavy-chain only IgG …
Antibodies to combat viral infections: development strategies and progress
Monoclonal antibodies (mAbs) are appealing as potential therapeutics and prophylactics for
viral infections owing to characteristics such as their high specificity and their ability to …
viral infections owing to characteristics such as their high specificity and their ability to …
Nanotechnology-based strategies against SARS-CoV-2 variants
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already infected more
than 500 million people globally (as of May 2022), creating the coronavirus disease 2019 …
than 500 million people globally (as of May 2022), creating the coronavirus disease 2019 …
[HTML][HTML] Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection
Immune protection following either vaccination or infection with SARS-CoV-2 is thought to
decrease over time. We designed a retrospective study, conducted at Leumit Health …
decrease over time. We designed a retrospective study, conducted at Leumit Health …
Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus is continuously
evolving, and this poses a major threat to antibody therapies and currently authorized …
evolving, and this poses a major threat to antibody therapies and currently authorized …
Targetable elements in SARS-CoV-2 S2 subunit for the design of pan-coronavirus fusion inhibitors and vaccines
L Guo, S Lin, Z Chen, Y Cao, B He, G Lu - Signal Transduction and …, 2023 - nature.com
The ongoing global pandemic of coronavirus disease 2019 (COVID-19), caused by severe
acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has caused devastating impacts …
acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has caused devastating impacts …
Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA. 1, BA. 2, and BA. 4/5 and diverse sarbecoviruses
Abstract As SARS-CoV-2 Omicron and other variants of concern (VOCs) continue spreading
worldwide, development of antibodies and vaccines to confer broad and protective activity is …
worldwide, development of antibodies and vaccines to confer broad and protective activity is …
Structural and biochemical mechanism for increased infectivity and immune evasion of Omicron BA. 2 variant compared to BA. 1 and their possible mouse origins
The Omicron BA. 2 variant has become a dominant infective strain worldwide. Receptor
binding studies show that the Omicron BA. 2 spike trimer exhibits 11-fold and 2-fold higher …
binding studies show that the Omicron BA. 2 spike trimer exhibits 11-fold and 2-fold higher …